CervoMed Inc.
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of th… Read more
CervoMed Inc. (CRVO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.249x
Based on the latest financial reports, CervoMed Inc. (CRVO) has a cash flow conversion efficiency ratio of -0.249x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.47 Million) by net assets ($26.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CervoMed Inc. - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how CervoMed Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CervoMed Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CervoMed Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kobay Tech Bhd
KLSE:6971
|
0.071x |
|
EuroDry Ltd
NASDAQ:EDRY
|
0.050x |
|
Sharp Therapeutics Corp.
V:SHRX
|
N/A |
|
New Peoples Bankshares Inc
PINK:NWPP
|
0.059x |
|
First Phosphate Corp.
OTCQB:FRSPF
|
-0.152x |
|
Honyi International Company Limited
TWO:4530
|
N/A |
|
E& Corporation CO. LTD
KQ:066980
|
0.016x |
|
Hexagon Purus ASA
PINK:HPURF
|
-0.139x |
Annual Cash Flow Conversion Efficiency for CervoMed Inc. (1998–2024)
The table below shows the annual cash flow conversion efficiency of CervoMed Inc. from 1998 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $39.20 Million | $-16.53 Million | -0.422x | +58.25% |
| 2023-12-31 | $7.38 Million | $-7.45 Million | -1.010x | -453.20% |
| 2022-12-31 | $-9.00 Million | $-2.57 Million | 0.286x | +168.83% |
| 2021-12-31 | $34.91 Million | $-14.50 Million | -0.415x | +23.94% |
| 2020-12-31 | $24.81 Million | $-13.55 Million | -0.546x | -11.55% |
| 2019-12-31 | $20.13 Million | $-9.86 Million | -0.490x | +29.04% |
| 2018-12-31 | $15.61 Million | $-10.77 Million | -0.690x | -18.79% |
| 2017-12-31 | $21.23 Million | $-12.33 Million | -0.581x | +50.45% |
| 2016-12-31 | $9.18 Million | $-10.77 Million | -1.172x | -100.94% |
| 2015-12-31 | $-41.62K | $-5.19 Million | 124.578x | +52752.75% |
| 2014-12-31 | $38.17 Million | $-9.03 Million | -0.237x | -29.13% |
| 2013-12-31 | $6.47 Million | $-1.18 Million | -0.183x | -178.24% |
| 2012-12-31 | $-18.41 Million | $-4.31 Million | 0.234x | -68.84% |
| 2011-12-31 | $-16.00 Million | $-12.02 Million | 0.751x | +100.77% |
| 2010-12-31 | $20.22K | $-1.98 Million | -97.964x | -4474.39% |
| 2009-12-31 | $493.60K | $-1.06 Million | -2.142x | -85.81% |
| 2008-12-31 | $438.99K | $-505.95K | -1.153x | +61.74% |
| 1999-12-31 | $2.77 Million | $-8.35 Million | -3.012x | -133.32% |
| 1998-12-31 | $5.50 Million | $-7.10 Million | -1.291x | -- |